Clinical trial
A Phase 2 Trial of Amrubicin With or Without Herceptin in the Treatment of Metastatic Breast Cancer
NCT00380835 is registered in ClinicalTrials.gov with Celgene Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Trial of Amrubicin With or Without Herceptin in the Treatment of Metastatic Breast Cancer
- Lead sponsor
- Celgene Corporation
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- Not reported
- Completion date
- December 31, 2007
- Enrollment
- 66 (estimated)
- Sites
- 28
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic breast cancer